Calliditas Therapeutics AB
STO:CALTX
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
91.1
208.2
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Calliditas Therapeutics AB
Calliditas Therapeutics AB
Accrued Liabilities
Calliditas Therapeutics AB
Accrued Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accrued Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Calliditas Therapeutics AB
STO:CALTX
|
Accrued Liabilities
kr252.1m
|
CAGR 3-Years
67%
|
CAGR 5-Years
106%
|
CAGR 10-Years
N/A
|
|
|
Camurus AB
STO:CAMX
|
Accrued Liabilities
kr251.8m
|
CAGR 3-Years
22%
|
CAGR 5-Years
22%
|
CAGR 10-Years
N/A
|
|
|
S
|
Swedencare AB (publ)
STO:SECARE
|
Accrued Liabilities
kr78.5m
|
CAGR 3-Years
53%
|
CAGR 5-Years
94%
|
CAGR 10-Years
N/A
|
|
|
IRLAB Therapeutics AB
STO:IRLAB A
|
Accrued Liabilities
kr14.9m
|
CAGR 3-Years
8%
|
CAGR 5-Years
38%
|
CAGR 10-Years
N/A
|
|
|
Moberg Pharma AB (publ)
STO:MOB
|
Accrued Liabilities
kr9.2m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
I
|
InDex Pharmaceuticals Holding AB
STO:FLERIE
|
Accrued Liabilities
kr5.4m
|
CAGR 3-Years
24%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
Calliditas Therapeutics AB
Glance View
Calliditas Therapeutics AB clinical-stage biopharmaceutical company. The company is headquartered in Stockholm, Stockholm. The company went IPO on 2018-06-29. The company is focused on the development and commercialization of its product candidate Nefecon, a treatment for patients with inflammatory kidney disease (IgA nephropathy) who are at risk of progressing to renal failure. Nefecon is derived from the TARGIT technology, in which the capsule containing the active drug substance is coated in a way that the capsule remains intact as it passes through the stomach and intestine until it reaches the lower small intestine, where the release of content takes place. Nefeco combines time lag effect with a concentrated release of the active substance budesonide, within a designated target area.
See Also
What is Calliditas Therapeutics AB's Accrued Liabilities?
Accrued Liabilities
252.1m
SEK
Based on the financial report for Jun 30, 2024, Calliditas Therapeutics AB's Accrued Liabilities amounts to 252.1m SEK.
What is Calliditas Therapeutics AB's Accrued Liabilities growth rate?
Accrued Liabilities CAGR 5Y
106%
Over the last year, the Accrued Liabilities growth was 34%. The average annual Accrued Liabilities growth rates for Calliditas Therapeutics AB have been 67% over the past three years , 106% over the past five years .
You don't have any saved screeners yet
